BTX BioTime, Inc. Common Stock

3.17
0  0%
Previous Close 3.18
Open 3.17
Price To book 2.77
Market Cap 325.80M
Shares 102,776,000
Volume 239,041
Short Ratio 9.72
Av. Daily Volume 398,281

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 six and nine-month data released January 24, 2017 from AIS-A 10 million-cell cohort. 12-month efficacy and safety data for this cohort, as well as 6-month efficacy and safety data for the currently-enrolling AIS-A 20 million cell and AIS-B 10 million cell cohorts, due 3Q 2017.
AST-OPC1 - SCiStar
Cervical spinal cord injury
Pivotal trial data due by mid-2017.
Renevia
Restoring normal skin contours in for patients with HIV
Phase 2 second cohort underway. Data due May 8, 2017 at ARVO conference.
OpRegen
Dry age-related macular degeneration (AMD)
Phase 2b planned for 2018.
AST-VAC1
Maintenance of relapse-free-survival in acute myeloid leukemia (AML)

Latest News

  1. BioTime, Inc. is trading below its 50 day moving average : BTX-US : April 21, 2017
  2. BioTime, Inc. – Value Analysis (NYSE MKT:BTX) : April 20, 2017
  3. BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : April 19, 2017
  4. ETFs with exposure to BioTime, Inc. : April 13, 2017
  5. BioTime Forms New Subsidiary AgeX Therapeutics, Inc. to Develop its Programs Focused on Human Aging
  6. BioTime Co-CEO Dr. Michael West to Deliver Keynote Presentation at GTC Bio Stem Cell Summit on April 6
  7. Key BioTime Patents Upheld by European Patent Office
  8. BioTime, Inc.: Trading close to its 50 day moving average. Good buy?
  9. BioTime, Inc. is trading above its 50 day moving average : BTX-US : March 22, 2017
  10. BioTime, Inc. :BTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  11. BioTime, Inc.: Strong price momentum but will it sustain?
  12. BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : March 20, 2017
  13. BioTime to Present at Oppenheimer 27th Annual Healthcare Conference
  14. BioTime, Inc. Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments
  15. Data From BioTime’s OpRegen® Trial in Dry-AMD to be Presented at ARVO on May 8
  16. BioTime Expands OpRegen® Clinical Trial in Dry-AMD With Opening of First US Sites
  17. BioTime, Inc. breached its 50 day moving average in a Bearish Manner : BTX-US : March 8, 2017
  18. BioTime, Inc. : Undervalued relative to peers, but don’t ignore the other factors
  19. BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : February 24, 2017
  20. BioTime, Inc. to Announce Fourth Quarter and Fiscal 2016 Results on March 16, 2017